Redeye initiates coverage of IDL Biotech, aiming to transform the management of patients with bladder cancer and other life-threatening diseases through quicker and more cost-effective diagnosis. Past mis-steps in execution have hurt company’s credibility and at current EV of 100 MSEK, investors are failing to price any future growth.